A Phase 2 interventional study of Nivolumab and Ipilimumab in Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney and Epithelioid Sarcoma, sponsored by Dana-Farber Cancer Institute. Active, not recruiting at 8 sites in United States. Open to participants aged 6 Months to 40 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Treatment
How we know · 5 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Rhabdoid Tumor with a site in United States — 18 open to participants now, 39 under way, none of them phase 3. Rhabdoid Tumor · United States.
Among the 103 studies in Rhabdoid Tumor with a site in United States, this one is the 42nd largest by enrollment of the 92 interventional ones that give a count, is one of 8 that started in 2020, is one of 28 in phase 2, reaches primary completion later than 11 of the 38 other live ones, and was the 77th registered.
115 studies on the registry are indexed under Rhabdoid Tumor; 23 are open to participants now.
Browse Rhabdoid Tumor studies →18 of the 103 studies in Rhabdoid Tumor with a site in United States are open now. Recruiting first, the newest first:
Robbie Majzner · Sites in United States
Ages 2–21
Children's National Research Institute · Sites in United States
Ages 3–25
Sabine Mueller, MD, PhD · Sites in United States
Ages 1–39
Milton S. Hershey Medical Center · Sites in United States
Ages up to 26
University of Florida · Sites in United States
Ages 6 mo–25 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Rhabdoid Tumor studies recruiting now, 2 (10%) set no upper age limit and 18 (90%) stop at 75 or younger; 20 take children under 18; none take healthy volunteers.
This study: 6 Months to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 36 · Phase 3 3
First in 1992; this study’s year is marked. 8 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is close to the median of 28 across 98 interventional studies indexed under Rhabdoid Tumor.
Median enrollment 28 across the 92 interventional studies, 98 across the 10 observational. Of the 59 that completed or were terminated, 18 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 103 have an industry lead sponsor. The 10 most frequent:
Dana-Farber Cancer Institute is the lead sponsor of 836 studies on the registry; 121 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 78 (68%) have results posted.
Dana-Farber Cancer Institute has 3 studies filed under Rhabdoid Tumor — fewer than ten, so there is no comparison to draw.
8 of the studies in Rhabdoid Tumor with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04901702St. Jude Children's Research HospitalStudy of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | 2026-12-31 |
| NCT04099797Baylor College of MedicineC7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) | 2027-02 |
| NCT05407441Susan Chi, MDTazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | 2027-02-01 |
| NCT04897321St. Jude Children's Research HospitalB7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | 2027-03-01 |
| NCT04185038Seattle Children's HospitalStudy of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 103 studies in Rhabdoid Tumor with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug or drug combination to learn whether the drug or drug combination works in treating a specific disease. "Investigational" means that the drug combination is being studied.
The names of the study drugs involved in this study are:
This trial is studying whether nivolumab and ipilimumab work to treat INI1-negative cancers.
The U.S. Food and Drug Administration (FDA) has not approved combination nivolumab and ipilimumab for the specific diseases in this study but it has been approved for other diseases. Nivolumab and ipilimumab have been tested in children to find out a safe dose of this combination.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All participants must have one of the following confirmed tumors at original diagnosis or relapse:
Stratum 1
Stratum 2
All participants must have tumor assessment at original diagnosis or relapse showing the following:
Participants must have fully recovered from the acute toxic effects of all prior anti-cancer therapy. Participants must meet the following minimum prior to first day of study treatment:
Radiotherapy
Participants must have adequate organ function as defined below
Bone Marrow Function
Hepatic Function
Renal function
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Patients will receive combination therapy with nivolumab at a predetermined dose and ipilimumab at a predetermined dose day 1 of a 21-day cycle for 4 cycles * Starting with cycle 5, patients will receive nivolumab monotherapy at a predetermined dose on day 1 and day 15 of a 28-day cycle * Patients with INI1-negative relapsed or refractory extracranial solid tumors
Drug: Nivolumab · Drug: Ipilimumab
* Patients will receive combination therapy with nivolumab at a predetermined dose and ipilimumab at a predetermined dose day 1 of a 21-day cycle for 4 cycles * Starting with cycle 5, patients will receive nivolumab monotherapy at a predetermined dose on day 1 and day 15 of a 28-day cycle * Patients with INI1-negative relapsed or refractory CNS tumors
Drug: Nivolumab · Drug: Ipilimumab
Combination Therapy: Nivolumab at predetermined dosage day 1 of a 21-day cycle for 4 cycles. Monotherapy: Starting with cycle 5 nivolumab at predetermined dosage on day 1 and day 15 of a 28-day cycle
Also known as: OPDIVO
Combination Therapy: Ipilimumab at predetermined dosage day 1 of a 21-day cycle for 4 cycles
Also known as: YERYOY
Objective Response Rate (ORR)
ORR is defined as the percentage of participants who achieved a complete response (CR) or a partial response (PR), as measured by RECIST 1.1 for Stratum 1 and RANO for Stratum 2 per local assessment.
Time frame: 12 months
Progression-free Survival (EFS) at 3 Months
Progression-free survival (PFS) was defined as the time from study enrollment until the first occurrence of disease progression, relapse or death due to disease; patients without an event were censored at date of last disease evaluation.
Time frame: 3 months
Overall Survival (OS) at 3 Months
OS based on the Kaplan-Meier method is defined as the time from randomization to death. Participants alive are censored at the last date of contact (including lost-to-follow-up) or at the date of withdrawal of consent, if relevant.
Time frame: 3 months
Disease Control Rate at 12 Months (DCR12)
DCR12 is defined as the percentage of participants who are progression-free at 12 months. Progression disease (PD) is assessed using RECIST criteria for Stratum 1 and RANO criteria for Stratum 2.
Time frame: 12 Months
| Milestone | Solid Tumor (Stratum 1) | CNS Tumors (Stratum 2) |
|---|---|---|
| Started | 23 | 7 |
| Completed | 19 | 7 |
| Not completed | 4 | 0 |
| Withdrew: Follow up | 1 | 0 |
| Withdrew: Taken off study prior to starting treatment | 3 | 0 |
ORR is defined as the percentage of participants who achieved a complete response (CR) or a partial response (PR), as measured by RECIST 1.1 for Stratum 1 and RANO for Stratum 2 per local assessment.
| Percentage of participants | Solid Tumor (Stratum 1) | CNS Tumors (Stratum 2) |
|---|---|---|
| Objective Response Rate (ORR) | 5 (0.1 to 25) | 0 (0 to 41) |
Progression-free survival (PFS) was defined as the time from study enrollment until the first occurrence of disease progression, relapse or death due to disease; patients without an event were censored at date of last disease evaluation.
| Percentage of participants | Solid Tumor (Stratum 1) | CNS Tumors (Stratum 2) |
|---|---|---|
| Progression-free Survival (EFS) at 3 Months | 15 (4 to 33) | 14 (0.7 to 46) |
OS based on the Kaplan-Meier method is defined as the time from randomization to death. Participants alive are censored at the last date of contact (including lost-to-follow-up) or at the date of withdrawal of consent, if relevant.
| Percentage of participants | Solid Tumor (Stratum 1) | CNS Tumors (Stratum 2) |
|---|---|---|
| Overall Survival (OS) at 3 Months | 60 (36 to 78) | 71 (26 to 92) |
DCR12 is defined as the percentage of participants who are progression-free at 12 months. Progression disease (PD) is assessed using RECIST criteria for Stratum 1 and RANO criteria for Stratum 2.
| percentage of participants | Solid Tumor (Stratum 1) | CNS (Stratum 2) |
|---|---|---|
| Disease Control Rate at 12 Months (DCR12) | 5 (0.1 to 25) | 0 (0 to 41) |
Collected over Adverse Events from enrollment to 30 days after last dose of study treatment (Treatment up to 12 months). Serious Adverse Events from enrollment to 100 days after last dose of study treatment. All-Cause Mortality up to 2 years after last dose of study treatment (Treatment up to 12 months).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Solid Tumor (Stratum 1) | 16/20 (80%) | 15/20 (75%) | 20/20 (100%) |
| CNS Tumors (Stratum 2) | 5/7 (71.4%) | 3/7 (42.9%) | 7/7 (100%) |
| Event | Solid Tumor (Stratum 1) | CNS Tumors (Stratum 2) |
|---|---|---|
| Disease progressionGeneral disorders | 9/20 | 2/7 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 4/20 | 0/7 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 4/20 | 0/7 |
| Abdominal painGastrointestinal disorders | 3/20 | 0/7 |
| Tumor painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/20 | 0/7 |
| VomitingGastrointestinal disorders | 2/20 | 1/7 |
| HydrocephalusNervous system disorders | 0/20 | 1/7 |
| SomnolenceNervous system disorders | 0/20 | 1/7 |
| Nervous system disorders - Other, specifyNervous system disorders | 0/20 | 1/7 |
| Surgical and medical procedures - Other, specifySurgical and medical procedures | 0/20 | 1/7 |
| Event | Solid Tumor (Stratum 1) | CNS Tumors (Stratum 2) |
|---|---|---|
| AnemiaBlood and lymphatic system disorders | 13/20 | 7/7 |
| FatigueGeneral disorders | 10/20 | 6/7 |
| Lymphocyte count decreasedInvestigations | 16/20 | 3/7 |
| VomitingGastrointestinal disorders | 6/20 | 5/7 |
| White blood cell decreasedInvestigations | 8/20 | 4/7 |
| HypertensionVascular disorders | 6/20 | 4/7 |
| HypoalbuminemiaMetabolism and nutrition disorders | 11/20 | 1/7 |
| HyponatremiaMetabolism and nutrition disorders | 11/20 | 2/7 |
| Alanine aminotransferase increasedInvestigations | 4/20 | 3/7 |
| Aspartate aminotransferase increasedInvestigations | 6/20 | 3/7 |
This analysis only applied to participants who started study treatment, and does not included 3 participants who were enrolled on Stratum 1 and were taken off study prior to receiving any study treatment.
| Age, Continuous(Years) | Solid Tumor (Stratum 1) | CNS Tumors (Stratum 2) | Total |
|---|---|---|---|
| Mean | 12.4 (0.7 to 37.6) | 4.0 (0.6 to 8.6) | 7.1 (0.6 to 37.6) |
| Sex: Female, Male(Participants) | Solid Tumor (Stratum 1) | CNS Tumors (Stratum 2) | Total |
|---|---|---|---|
| Female | 9 | 3 | 12 |
| Male | 11 | 4 | 15 |
| Race (NIH/OMB)(Participants) | Solid Tumor (Stratum 1) | CNS Tumors (Stratum 2) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 9 | 1 | 10 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 8 | 6 | 14 |
| Ethnicity (NIH/OMB)(Participants) | Solid Tumor (Stratum 1) | CNS Tumors (Stratum 2) | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 15 | 2 | 17 |
| Unknown or Not Reported | 4 | 3 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data can be shared no earlier than 1 year following the date of publication
Access criteria: DFCI - Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
Ran from Aug 2020 to primary completion in Jul 2025, 59 months.
Results were first posted in Oct 2026, 1 year 3 months after primary completion.
Of 23 phase 2 interventional studies under Rhabdoid Tumor, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 89. This study's 59 months is close to that.
Completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jul 2027, on Oct 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Ipilimumab
Dana-Farber Cancer Institute →